Clin2
NCT06927739Possibly a fitRecruiting

Orticumab for heart artery inflammation after a heart attack

Acute Coronary SyndromesCoronary Arterial Disease (CAD)InflammationHeart DiseaseMyocardial InfarctAtherosclerotic Coronary Vascular Disease

Part of Heart & circulation clinical trials.

This trial tests a drug called orticumab to see if it can reduce inflammation in the arteries of the heart after a heart attack. It may help prevent future heart problems.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
240 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You had a heart attack more than 6 months ago.
  • You are on a stable heart medication plan (like a statin or other cholesterol pill).
  • You have a special heart CT scan showing a certain level of inflammation around your heart arteries.
  • Your body mass index (BMI) is 40 or less.
  • You are not pregnant, breastfeeding, and use effective birth control if needed.
  • You have not had recent COVID-19 vaccine or infection within the last 3 months.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06007248Recruiting
Study of inflammation-related coronary artery disease

This study compares two types of coronary artery disease: one linked to inflammation (IR-CAD) and the standard type (AS-CAD). If you have had a heart procedure and were recently hospitalized for worsening chest pain, this study may help doctors understand your condition better.

Beijing, Beijing Municipality
NCT05860400Recruiting
Testing add-on treatment to calm artery inflammation after heart procedures

This study looks at whether a comprehensive add-on treatment—starting with immune medicine and then a heart procedure when needed—can improve outcomes for people whose coronary artery disease is getting worse quickly. It focuses on cases where inflammation is likely driving new artery blockages or worsening chest pain.

Beijing, Beijing Municipality
NCT07276282Recruiting· Phase 3
Ziltivekimab for heart attack patients with artery plaque

This trial tests a new drug called Ziltivekimab to see if it can reduce plaque buildup in the heart arteries after a heart attack. It may help prevent future heart problems by targeting inflammation.

Bern
NCT06788431Recruiting· Early Phase 1
Study of IMC-001 to stabilize heart artery plaque

This trial tests an investigational drug, IMC-001, to see if it can make artery plaques in the heart more stable and less likely to cause a heart attack. You may be eligible if you've recently had a heart attack or unstable angina and have a specific type of soft plaque in your arteries.

Nanyang, Henan
NCT06227754Recruiting
OCT vs. angiography for heart attack treatment

This trial compares two ways to guide treatment during a heart attack: using a special camera (OCT) inside the artery or standard X-ray (angiography). It aims to see which method leads to better results for patients.

Daegu, Daegu
NCT07586540Not yet recruiting· Phase 3
Alirocumab to stabilize vulnerable carotid plaque

This trial tests whether alirocumab, a cholesterol-lowering injection, can stabilize dangerous plaque buildup in neck arteries (carotid arteries) that recently caused a mini-stroke or temporary vision loss. The goal is to reduce your risk of a future stroke.

Alexandria

Hear when a new Coronary Arterial Disease (CAD) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.